Clinical Trial Update: Long-term Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis [Phase 3]

View source ↗

Summary

This report presents long-term efficacy and safety data for fingolimod (FTY720) in patients with relapsing-remitting multiple sclerosis from a Phase 3 trial.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis
• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• GILENYA (FINGOLIMOD HCL)

Snippet

Sponsor: Novartis | Conditions: Multiple Sclerosis | Phase 3 | Status: COMPLETED | Results posted: 2012-07-12